Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis

摘要

The purpose of this analysis was to characterize, based on the FAERS database, the proportions of specific ISR terms reported for each subcutaneously administered biologic product approved in the US for the treatment of moderate-to-severe plaque psoriasis.